COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance - Sorbonne Université Access content directly
Journal Articles The Journal of rheumatology Year : 2022

COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance

Bernardo M. Cunha
  • Function : Author
Rachael Flood
  • Function : Author
Daria A. Kusevich
  • Function : Author
Suleman Bhana
  • Function : Author
Wendy Costello
  • Function : Author
Paul Sufka
  • Function : Author

Abstract

Objective To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24\textendash 45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti\textendash interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.

Dates and versions

hal-03892149 , version 1 (09-12-2022)

Identifiers

Cite

Bonnie L. Bermas, Milena Gianfrancesco, Helen L. Tanner, Andrea M. Seet, Mathia C. Aguiar, et al.. COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. The Journal of rheumatology, 2022, 49 (1), pp.110--114. ⟨10.3899/jrheum.210480⟩. ⟨hal-03892149⟩
18 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More